Last reviewed · How we verify
TEZ
TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface.
TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface. Used for Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor), Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulation.
At a glance
| Generic name | TEZ |
|---|---|
| Also known as | Tezacaftor, VX-661, tezacaftor |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | CFTR corrector |
| Target | CFTR (cystic fibrosis transmembrane conductance regulator) |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Genetic Disorders |
| Phase | FDA-approved |
Mechanism of action
TEZ works by binding to CFTR and assisting in proper protein folding, allowing the defective CFTR protein to reach the cell membrane where it can function. It is typically used in combination with ivacaftor (a CFTR potentiator) to enhance both the quantity and function of CFTR at the cell surface. This combination addresses the underlying defect in cystic fibrosis caused by certain CFTR mutations.
Approved indications
- Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor)
- Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulation
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Rash
- Transaminase elevation
Key clinical trials
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants (PHASE1)
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older (PHASE3)
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older (PHASE3)
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del (PHASE3)
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age (PHASE3)
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age (PHASE3)
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEZ CI brief — competitive landscape report
- TEZ updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI